Sutro Biopharma (NASDAQ: STRO) revenue
Sutro Biopharma reported revenue of $102.5m for fiscal 2025, 65.2% more than in fiscal 2024 ($62.0m). Since fiscal 2017 its revenue has grown by 98.1%, an average growth of 8.9% a year.
Sutro Biopharma's best year of the last 9 was fiscal 2023. The biggest drop was in fiscal 2024, −59.6%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $102.5m | +65.2% | −$158.4m | −154.5% |
| 2024 | $62.0m | −59.6% | −$238.5m | −384.3% |
| 2023 | $153.7m | +126.8% | −$89.3m | −58.1% |
| 2022 | $67.8m | +9.5% | −$128.9m | −190.3% |
| 2021 | $61.9m | +44.8% | −$98.5m | −159.2% |
| 2020 | $42.7m | 0.0% | −$71.1m | −166.3% |
| 2019 | $42.7m | +11.2% | −$55.5m | −129.8% |
| 2018 | $38.4m | −25.7% | −$37.2m | −96.9% |
| 2017 | $51.7m | — | −$19.3m | −37.2% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Sutro Biopharma revenue compared with its sector
By revenue for its latest fiscal year, Sutro Biopharma ranks 285th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Sutro Biopharma, 65.2%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 283rd | Zymeworks | $106.0m | 38.9% |
| 284th | Sanara Medtech | $103.1m | 19.0% |
| 285th | Sutro Biopharma | $102.5m | 65.2% |
| 286th | Beta Bionics | $100.3m | 53.9% |
| 287th | Neuropace | $100.0m | 25.1% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Sutro Biopharma
- How much revenue did Sutro Biopharma make in fiscal 2025?
- Sutro Biopharma reported revenue of $102.5m for fiscal 2025, compared with $62.0m in fiscal 2024.
- How much has the revenue of Sutro Biopharma grown?
- Between fiscal 2017 and fiscal 2025 it went from $51.7m to $102.5m: 98.1% more, an average growth of 8.9% a year.
- What was the best year for revenue at Sutro Biopharma?
- Of its last 9 fiscal years, fiscal 2023, with $153.7m.
- Where does Sutro Biopharma rank in its sector by revenue?
- It ranks 285th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Sutro Biopharma come from?
- From the annual report (Form 10-K) that Sutro Biopharma files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Sutro Biopharma files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017. More on Sutro Biopharma: the Sutro Biopharma page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.